Get the Stockscreener App
1.36
3.55%
-0.05
After Hours:
1.40
0.04
+2.94%
Werewolf Therapeutics Inc stock is traded at $1.36, with a volume of 158.23K.
It is down -3.55% in the last 24 hours and down -16.05% over the past month.
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.
See More
Previous Close:
$1.41
Open:
$1.43
24h Volume:
158.23K
Relative Volume:
0.40
Market Cap:
$60.61M
Revenue:
$19.94M
Net Income/Loss:
$-37.37M
P/E Ratio:
-1.3077
EPS:
-1.04
Net Cash Flow:
$-33.38M
1W Performance:
+0.74%
1M Performance:
-16.05%
6M Performance:
-31.31%
1Y Performance:
-79.08%
1-Day Range:
$1.35
$1.44
1-Week Range:
$1.26
$1.45
52-Week Range:
$1.26
$8.1939
Werewolf Therapeutics Inc Stock (HOWL) Company Profile
Name
Werewolf Therapeutics Inc
Sector
Industry
Phone
617-952-0555
Address
200 TALCOTT AVENUE, WATERTOWN
Compare HOWL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HOWL
Werewolf Therapeutics Inc
|
1.36 | 60.61M | 19.94M | -37.37M | -33.38M | -1.04 |
|
VRTX
Vertex Pharmaceuticals Inc
|
481.16 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.07 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
657.97 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
278.25 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
119.94 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Werewolf Therapeutics Inc Stock (HOWL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-03-24 | Initiated | JMP Securities | Mkt Outperform |
| Aug-24-23 | Initiated | Wedbush | Outperform |
| Jun-06-23 | Resumed | Jefferies | Buy |
| Sep-10-21 | Initiated | BofA Securities | Buy |
| May-25-21 | Initiated | Evercore ISI | Outperform |
| May-25-21 | Initiated | H.C. Wainwright | Buy |
| May-25-21 | Initiated | Jefferies | Buy |
| May-25-21 | Initiated | SVB Leerink | Outperform |
View All
Werewolf Therapeutics Inc Stock (HOWL) Latest News
Short Interest in Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Grows By 13.2% - MarketBeat
Harmony Biosciences (NASDAQ:HRMY) vs. Werewolf Therapeutics (NASDAQ:HOWL) Head to Head Review - Defense World
Barclays PLC Increases Stake in Werewolf Therapeutics, Inc. (NASDAQ:HOWL) - Defense World
Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Short Interest Up 13.2% in December - MarketBeat
Jane Street Group LLC Trims Holdings in Werewolf Therapeutics, Inc. (NASDAQ:HOWL) - Defense World
Werewolf Therapeutics' SWOT analysis: stock faces challenges amid pipeline progress - Investing.com
Werewolf Therapeutics (NASDAQ:HOWL) Price Target Lowered to $4.00 at JMP Securities - MarketBeat
JMP Securities Cuts Price Target for Werewolf Therapeutics (NASDAQ:HOWL) to $4.00/Share, Down from $12.00 - HPBL
Werewolf Therapeutics provides business update, highlights 2025 outlook - Yahoo Finance
Werewolf Therapeutics Provides Business Update - citybiz
Werewolf Therapeutics Provides Business Update and Highlights 2025 Strategic Outlook - GlobeNewswire
Werewolf Therapeutics Unveils Ambitious 2025 Pipeline Plans for Cancer Immunotherapy Programs - StockTitan
Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Shares Acquired by Geode Capital Management LLC - Defense World
Barclays PLC Buys 30,990 Shares of Werewolf Therapeutics, Inc. (NASDAQ:HOWL) - Defense World
State Street Corp Has $1.01 Million Position in Werewolf Therapeutics, Inc. (NASDAQ:HOWL) - Defense World
Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Short Interest Up 23.6% in December - MarketBeat
Werewolf Therapeutics stock hits 52-week low at $1.58 By Investing.com - Investing.com UK
Short Interest in Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Drops By 6.1% - Defense World
Short Interest in Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Declines By 6.1% - MarketBeat
Werewolf Therapeutics' SWOT analysis: oncology stock's potential amid clinical trials - Investing.com Australia
HC Wainwright Reaffirms “Buy” Rating for Werewolf Therapeutics (NASDAQ:HOWL) - Defense World
Werewolf Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Healthcare Conference - The Manila Times
Werewolf Therapeutics stock hits 52-week low at $1.62 - Investing.com India
Werewolf Therapeutics stock hits 52-week low at $1.62 By Investing.com - Investing.com Canada
Werewolf Therapeutics stock holds buy rating amid investor concerns over cytokine therapies By Investing.com - Investing.com Canada
HC Wainwright Reaffirms "Buy" Rating for Werewolf Therapeutics (NASDAQ:HOWL) - MarketBeat
PFM Health Sciences, LP Increases Stake in Werewolf Therapeutics Inc - GuruFocus.com
Werewolf Therapeutics (NASDAQ:HOWL) Has Debt But No Earnings; Should You Worry? - Simply Wall St
Equities Analysts Set Expectations for HOWL FY2024 Earnings - MarketBeat
Werewolf Therapeutics' SWOT analysis: oncology biotech's stock potential amid clinical progress - Investing.com Australia
What is HC Wainwright's Forecast for HOWL Q1 Earnings? - MarketBeat
Werewolf Therapeutics reports promising trial data for cancer drug By Investing.com - Investing.com South Africa
Werewolf Therapeutics Inc (HOWL) Quarterly 10-Q Report - Quartz
Werewolf Therapeutics reports promising trial data for cancer drug - Investing.com
Werewolf Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update - GlobeNewswire
Werewolf Therapeutics Presents Preclinical and Clinical - GlobeNewswire
Werewolf's WTX-330 Shows Promise in Phase 1 Trial: Melanoma Patient Responds to Novel IL-12 Therapy | HOWL Stock News - StockTitan
Werewolf Therapeutics Reports Breakthrough Cancer Trial Results Despite $16.7M Loss | HOWL Stock News - StockTitan
Werewolf Therapeutics announces IL-10 Indukine development candidate for inflammatory bowel disease - BioWorld Online
Werewolf Therapeutics expands pipeline with new IBD candidate By Investing.com - Investing.com South Africa
Werewolf Therapeutics expands pipeline with new IBD candidate - Investing.com
Werewolf Therapeutics Announces Promising New Development Candidate, WTX-921, a first-of-its-kind IL-10 INDUKINE™ Molecule for Inflammatory Diseases - The Manila Times
Werewolf Therapeutics Announces Promising New Development - GlobeNewswire
WisdomTree Inc (NYSE: WT): Blank Check On Growth? - Stocks Register
Werewolf To Provide Clinical Update On WTX-330 - RTTNews
Werewolf Therapeutics Inc (NASDAQ: HOWL) Could Pass $12 In One Year Stock Forecast - Stocks Register
Social Security Just Released the 2025 COLA. Here's What It Means for Those Receiving Spousal Benefits. - Yahoo! Voices
Werewolf Therapeutics Inc Stock (HOWL) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.82%
0.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):